World Health Organization site
Skip Navigation Links

Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: ClinicalTrials.gov
Last refreshed on: 16 December 2017
Main ID:  NCT01136213
Date of registration: 26/05/2010
Prospective Registration: No
Primary sponsor: University Hospital, Bordeaux
Public title: Investigation of the Serotoninergic System in Multiple System Atrophy: a Positron Emission Tomography (PET) Study SEROTAMS
Scientific title: Morphological and Functional Investigation of the Serotoninergic System in Multiple System Atrophy: a 18F-MPPF PET Study
Date of first enrolment: April 2010
Target sample size: 53
Recruitment status: Completed
URL:  https://clinicaltrials.gov/show/NCT01136213
Study type:  Observational
Study design:   
Phase:  N/A
Countries of recruitment
France
Contacts
Name:     Igor SIBON, Pr
Address: 
Telephone:
Email:
Affiliation:  University Hospital Bordeaux (France)
Name:     Geneviève CHENE, Pr
Address: 
Telephone:
Email:
Affiliation:  University Hospital Bordeaux (France)
Key inclusion & exclusion criteria

Inclusion Criteria:

- Patients with Multiple system atrophy (MSA)

- MSA possible or probable

- Male and female

- Age : 30 to 80

- No cognitive impairment

- Unmodified treatment for 2 months

- Able to give informed consent

- Affiliated to social insurance

- Patients with idiopathic Parkinson's disease (IPD):

- Positive clinical criteria for IPD

- Male and female

- Age : 30 to 80

- No cognitive impairment

- Unmodified treatment for 2 months

- Able to give informed consent

- Affiliated to social insurance

- Healthy controls:

- Absence of neuropsychiatric disorder

- Male and female

- Age : 30 to 80

- Able to give informed consent

- Affiliated to social insurance

Exclusion Criteria:

- Patients with Multiple system atrophy (MSA)

- Other Parkinsonian syndrome

- Dementia

- Recent intake (< 4 weeks or 8 weeks for fluoxetine) of medication acting on
5-HT1a receptors

- History of major depression

- Contraindication to brain MRI

- Contraindication to PET

- Patients with idiopathic Parkinson's disease

- Other Parkinsonian syndrome

- Dementia

- Recent intake (< 4 weeks or 8 weeks for fluoxetine) of medication acting on
5-HT1a receptors

- History of major depression

- Contraindication to brain MRI

- Contraindication to PET

- Healthy controls:

- Patient having a neuropsychiatric disease

- Recent intake (< 4 weeks or 8 weeks for fluoxetine) of medication acting on
5-HT1a receptors

- History of major depression

- Contraindication to brain MRI

- Contraindication to PET



Age minimum: 30 Years
Age maximum: 80 Years
Gender: All
Health Condition(s) or Problem(s) studied
Multiple System Atrophy
Intervention(s)
Drug: Fluoxétine / Placebo
Other: Brain MRI (magnetic resonance imaging)
Radiation: PET (Positron Emission Tomography) Study
Primary Outcome(s)
18F-MPPF binding potential - Biding potential (BP) under placebo in the raphe nucleus [Time Frame: Second visit (day 1)]
Secondary Outcome(s)
18F-MPPF binding potential - BP under fluoxetine in all brain areas [Time Frame: Third visit (day 30)]
18F-MPPF binding potential - Biding potential (BP) under placebo in other brain areas [Time Frame: Third visit (day 30)]
18F-MPPF binding potential - Biding potential (BP) in other brain areas [Time Frame: Second visit (day 1)]
Clinical parameters (motor handicap, orthostatic hypotension, quality of life, sleep, pain, tiredness) [Time Frame: Third visit (day 30)]
Clinical parameters (motor handicap, orthostatic hypotension, quality of life, sleep, pain, tiredness) [Time Frame: Second visit (day 1)]
Secondary ID(s)
CHUBX 2008/01
Source(s) of Monetary Support
Please refer to primary and secondary sponsors
Secondary Sponsor(s)
Ethics review
Results
Results available:
Date Posted:
Date Completed:
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history